I Scharrer

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
    I Scharrer
    Hemophilia Center, University of Frankfurt, Frankfurt, Germany
    Haemophilia 6:614-8. 2000
  2. ncbi Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII
    I Scharrer
    Center of Internal Medicine, University Hospital, Frankfurt, Germany Baxter Hyland Immuno, Vienna, Austria
    Haemophilia 7:346-8. 2001
  3. ncbi Women with von Willebrand disease
    I Scharrer
    Haemophilia Center, University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Hamostaseologie 24:44-9. 2004
  4. ncbi [Liver cirrhosis and coagulopathy]
    I Scharrer
    Abt für Hämostaseologie, J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main
    Hamostaseologie 25:205-8. 2005
  5. ncbi [Replacement therapy of coagulation factor preparations: antithrombin, FFP, PPSB, FXIII, rFVIIa]
    I Scharrer
    Abt für Hämostaseologie, J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main
    Hamostaseologie 25:209-12. 2005
  6. ncbi [Haemostaseological diseases on the intensive care units: TTP, HUS, spontaneous acquired FVIII inhibitor haemophilia and catastrophic antiphospholipid syndrome]
    I Scharrer
    Universitätskliniken Frankfurt am Main, Hämophilieambulanz, Theodor Stern Kai 7, 60590 Frankfurt Main
    Hamostaseologie 25:200-4. 2005
  7. ncbi Experience with KOGENATE Bayer in surgical procedures
    I Scharrer
    Frankfurt University Hospital, Frankfurt, Germany
    Haemophilia 8:15-8. 2002
  8. ncbi [Thrombophilic and systemic risk factors in patients with retinal vein occlusion]
    C Kuhli-Hattenbach
    Klinik fur Augenheilkunde, Universitätsklinikum Johann Wolfgang Goethe Universität, Theodor Stern Kai 7, 60590 Frankfurt am Main, Deutschland
    Ophthalmologe 108:104-10. 2011
  9. ncbi [Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age]
    C Kuhli-Hattenbach
    Klinik fur Augenheilkunde, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Klin Monbl Augenheilkd 225:1065-9. 2008
  10. ncbi [The antiphospholipid syndrome]
    W Miesbach
    Hämostaseologie, Zentrum der Inneren Medizin, Medizinische Klinik III, Universitätsklinik Frankfurt Main
    Dtsch Med Wochenschr 129:2547-52. 2004

Detail Information

Publications42

  1. ncbi Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
    I Scharrer
    Hemophilia Center, University of Frankfurt, Frankfurt, Germany
    Haemophilia 6:614-8. 2000
    ..It is concluded that rFVIII-SF is efficacious and safe in severe haemophilia A patients undergoing minor or major surgery...
  2. ncbi Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII
    I Scharrer
    Center of Internal Medicine, University Hospital, Frankfurt, Germany Baxter Hyland Immuno, Vienna, Austria
    Haemophilia 7:346-8. 2001
    ..De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation...
  3. ncbi Women with von Willebrand disease
    I Scharrer
    Haemophilia Center, University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Hamostaseologie 24:44-9. 2004
    ..Laboratory monitoring and therapeutical measures should be continued for 8-10 days after delivery. During menopause the clinical situation improves for most of the women with mild or moderate VWD...
  4. ncbi [Liver cirrhosis and coagulopathy]
    I Scharrer
    Abt für Hämostaseologie, J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main
    Hamostaseologie 25:205-8. 2005
    ..In patients with chronic liver disease profound coagulation changes and thrombocytopenia may lead to life-threatening bleeding that requires thorough diagnosis and immediate blood product replacement...
  5. ncbi [Replacement therapy of coagulation factor preparations: antithrombin, FFP, PPSB, FXIII, rFVIIa]
    I Scharrer
    Abt für Hämostaseologie, J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main
    Hamostaseologie 25:209-12. 2005
    ..Replacement therapy of coagulation factor preparations (AT, FFP, PPSB, FXIII, rFVIIa) are frequently used on the Intensive Care Units. Indications, dosage, specific effects and side effects have to be considered...
  6. ncbi [Haemostaseological diseases on the intensive care units: TTP, HUS, spontaneous acquired FVIII inhibitor haemophilia and catastrophic antiphospholipid syndrome]
    I Scharrer
    Universitätskliniken Frankfurt am Main, Hämophilieambulanz, Theodor Stern Kai 7, 60590 Frankfurt Main
    Hamostaseologie 25:200-4. 2005
    ..Especially patients with TTP, HUS, acquired haemophilia and CAPS have a poor prognosis. These emergency cases require a rapid diagnosis and an immediate onset of treatment...
  7. ncbi Experience with KOGENATE Bayer in surgical procedures
    I Scharrer
    Frankfurt University Hospital, Frankfurt, Germany
    Haemophilia 8:15-8. 2002
    ..No adverse events were recorded that were related to study drug. No viral seroconversions were observed. In conclusion, KOGENATE Bayer was shown to be safe and efficacious in patients with severe haemophilia A during surgical procedures...
  8. ncbi [Thrombophilic and systemic risk factors in patients with retinal vein occlusion]
    C Kuhli-Hattenbach
    Klinik fur Augenheilkunde, Universitätsklinikum Johann Wolfgang Goethe Universität, Theodor Stern Kai 7, 60590 Frankfurt am Main, Deutschland
    Ophthalmologe 108:104-10. 2011
    ..According to these data, thrombophilia screening should be considered in these selected subgroups...
  9. ncbi [Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age]
    C Kuhli-Hattenbach
    Klinik fur Augenheilkunde, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Klin Monbl Augenheilkd 225:1065-9. 2008
    ..The potential impact of coagulation abnormalities on non-arteritic ischaemic optic neuropathy (NAION), individually and in combination with cardiovascular risk factors, remains unclear...
  10. ncbi [The antiphospholipid syndrome]
    W Miesbach
    Hämostaseologie, Zentrum der Inneren Medizin, Medizinische Klinik III, Universitätsklinik Frankfurt Main
    Dtsch Med Wochenschr 129:2547-52. 2004
    ....
  11. ncbi A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation
    V Schachinger
    Department of Internal Medicine IV, Goethe University, Frankfurt
    Circulation 100:1502-8. 1999
    ..The aim of the study was to determine whether a positive family history of coronary artery disease is related to impaired coronary blood flow regulation...
  12. ncbi [Selective thrombophilia screening of young patients with retinal vein occlusion]
    C Kuhli-Hattenbach
    Klinik fur Augenheilkunde, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Klin Monbl Augenheilkd 226:768-73. 2009
    ..The potential impact of coagulation abnormalities on retinal vascular occlusive diseases, individually and in combination with cardiovascular risk factors, remains unclear...
  13. ncbi [Cardiac and cerebral manifestations of antiphospholipid syndrome]
    F Jung
    Johann Wolfgang Goethe Universität Frankfurt M Medizinische Klinik IV Abteilung Kardiologie Theodor Stern Kai 7 60590 Frankfurt M, Germany
    Z Kardiol 91:650-8. 2002
    ..We describe cardiac and cerebral manifestations in 27 patients with the antiphospholipid syndrome and give a review of the literature...
  14. ncbi The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma
    M T Forster
    Department of Neurosurgery, Goethe University Frankfurt am Main, Schleusenweg 2 16, D 60528 Frankfurt am Main, Germany
    J Clin Neurosci 17:975-9. 2010
    ..05). Reoperation is the strongest predictive factor of a poor QoL after surgical treatment of CSDH. Both preoperative and postoperative anticoagulation treatment may affect reoperation rate and, thus, postoperative QoL...
  15. ncbi Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion
    L O Hattenbach
    Department of Ophthalmology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Ophthalmologica 213:360-6. 1999
    ..Further investigation will be required to definitively prove the effectiveness of fibrinolytic agents...
  16. ncbi Prothrombotic risk factors in childhood stroke and venous thrombosis
    C Heller
    Department of Paediatrics, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Eur J Pediatr 158:S117-21. 1999
    ..CONCLUSION: Our results indicate that FV Leiden mutation and protein C deficiency may contribute to the multifactorial aetiology of stroke in early childhood...
  17. ncbi [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
    S Ehrenforth
    Zentrum der Inneren Medizin, Johann Wolfgang Goethe Universitat Frankfurt Main
    Dtsch Med Wochenschr 124:783-7. 1999
    ....
  18. ncbi Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group
    S Ehrenforth
    Department of Internal Medicine, University Hospital Frankfurt, Germany
    Eur J Pediatr 158:S97-104. 1999
    ..CONCLUSION: In conclusion, data of this multicentre evaluation indicate that paediatric thromboembolism should be viewed as a multifactorial disorder...
  19. ncbi Frequencies of GB virus C/hepatitis G virus genomes and of specific antibodies in German risk and non-risk populations
    C M Nübling
    Paul Ehrlich Institut, Langen, Germany
    J Med Virol 53:218-24. 1997
    ..Probable transmission of GBV-C/HGV by PCR-positive blood transfusions was observed in 5 of 6 cases approximately six months after transfusion...
  20. ncbi Central retinal vein occlusion and nonarteritic ischemic optic neuropathy in 2 patients with mild iron deficiency anemia
    B Kacer
    Klinik fur Augenheilkunde, Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main, Deutschland
    Ophthalmologica 215:128-31. 2001
    ..Clinicians involved in the management of chronic iron deficiency anemia should be aware of possible ophthalmic manifestations in this disease...
  21. ncbi Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand's syndrome
    B Braden
    Medical Department II, Johann Wolfgang Goethe Universitat, Frankfurt Main, Germany
    Helicobacter 3:184-7. 1998
    ..pylori infection in patients with hemophilia A or B and with the von Willebrand syndrome...
  22. ncbi Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism
    S Ehrenforth
    Department of Internal Medicine, University Hospital, Frankfurt am Main, Germany
    Arterioscler Thromb Vasc Biol 19:276-80. 1999
    ..7% (14 of 181). We conclude that the A20210 allele of the prothrombin gene is frequently coinherited in symptomatic FV:Q506 carriers and possibly influences age, site, and type of thrombotic onset manifestation in these patients...
  23. ncbi High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma
    W Miesbach
    Internal Medicine III, University Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Rheumatol 26:95-7. 2007
    ..In particular, haematological and lymphoproliferative malignancies may indeed be associated with the generation of aPL, but do not necessarily enhance the thrombophilic risk in these patients...
  24. ncbi Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation
    W Miesbach
    Internal Medicine, University Hospital, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Clin Rheumatol 23:256-61. 2004
    ..This case report shows that recurrent episodes of thrombosis can occur despite seemingly adequate anticoagulation in patients with CAPS...
  25. ncbi Coagulation disorders and the risk of retinal vein occlusion
    C Kuhli-Hattenbach
    Department of Ophthalmology, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Thromb Haemost 103:299-305. 2010
    ....
  26. ncbi Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates
    Ch von Auer
    Haemostaseology, Department of Internal Medicine III, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Ann N Y Acad Sci 1051:498-505. 2005
    ..Especially striking was the finding that 50% of the patients who developed inhibitors had mild to moderate hemophilia A. Our data point to the existence of a so-far unknown factor, related to CI, that might lead to inhibitor formation...
  27. ncbi Post-trauma coagulation and fibrinolysis in children suffering from severe cerebro-cranial trauma
    S Becker
    Department of Paediatrics, University Hospital Frankfurt am Main, Germany
    Eur J Pediatr 158:S197-202. 1999
    ..CONCLUSION: Our data underline the significance of post-trauma disturbances of the haemostatic system for the clinical course and outcome in children with severe cranio-cerebral injuries...
  28. ncbi Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden
    I Pabinger
    I Department of Internal Medicine, Division of Hematology Blood Coagulation, University Hospital, Vienna, Austria
    Hematol J 1:37-41. 2000
    ....
  29. ncbi Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience
    B Habermann
    Department of Orthopaedic Surgery, University Hospital Frankfurt/Main, Germany
    Haemophilia 10:705-12. 2004
    ..Our findings support data previously published...
  30. ncbi European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients
    C Rothschild
    Hospital Necker Enfants Malades, Paris, France
    Haemophilia 8:10-4. 2002
    ..No evidence of de novo inhibitor formation was observed. Overall, KOGENATE Bayer was efficacious, safe and well-tolerated for the treatment of haemophilia A in multitransfused patients...
  31. ncbi Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany
    G Auerswald
    Prof Hess Kinderklinik, Zentrum für Kinderheilkunde und Jugendmedizin, Bremen, Germany
    Haemophilia 10:499-508. 2004
    ..Assessing the results it has been taken into consideration that ITT can last longer and annual number of bleeds can be extremely higher than on average 12.5 episodes. This indicates more health care resource consumption in some patients...
  32. ncbi Total hip replacement in patients with severe bleeding disorders. A 30 years single center experience
    B Habermann
    Department of Orthopaedic Surgery, University Hospital Frankfurt Main, Marienburgstrasse 2, 60528, Frankfurt Main, Germany
    Int Orthop 31:17-21. 2007
    ..In conclusion, total hip replacement performed in a specialised haemophiliac centre is a safe procedure, and results in pain relief and improvement of the quality of life in patients with severe bleeding disorders...
  33. ncbi Hereditary thrombophilia and fetal loss: a prospective follow-up study
    C Y Vossen
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 2:592-6. 2004
    ..CONCLUSIONS: Women with thrombophilia appear to have an increased risk of fetal loss, although the likelihood of a positive outcome is high in both women with thrombophilia and in controls...
  34. ncbi Prevalence of a 23bp insertion in exon 3 of the endothelial cell protein C receptor gene in venous thrombophilia
    M Von Depka
    Department of Haematology Oncology, Hannover Medical School, Germany
    Thromb Haemost 86:1360-2. 2001
    ..However, the clinical significance of this mutation in VTE remains to be clarified...
  35. ncbi von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
    M Furlan
    Central Hematology Laboratory, University Hospital, Bern, Switzerland
    N Engl J Med 339:1578-84. 1998
    ..We investigated the prevalence of von Willebrand factor-cleaving protease deficiency in patients with familial and nonfamilial forms of these disorders...
  36. ncbi Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges?
    I Scharrer
    Haemophilia 10:197-8. 2004
  37. ncbi Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls
    A Pavlova
    Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
    Haemophilia 14:355-60. 2008
    ..In conclusion, on the background of the CTLA-4 gene polymorphism, further genetic and/or environmental factors might contribute to and finally trigger the clinical manifestation of AH...
  38. ncbi Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients
    A Borel Derlon
    Hemophilia Treatment Center, Caen University Hospital, Caen, France
    J Thromb Haemost 5:1115-24. 2007
    ..Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers...
  39. ncbi Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A
    S Bassus
    , Section Haemostasis, Wiesbaden, Germany
    Platelets 17:378-84. 2006
    ..The use of cell-based coagulation tests such us TGT or TEG may help to optimize FVIII therapy by determining the individual FVIII dosage that produces a maximum haemostatic effect...
  40. ncbi Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A
    S Ehrenforth
    Department of Internal Medicine I, University Hospital Frankfurt, Germany
    J Thromb Haemost 2:430-6. 2004
    ..Objectives: To assess the contribution of these factors on the thrombophilic phenotype...
  41. ncbi Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
    J Goudemand
    Haematology Institute, University Hospital, Lille, France
    J Thromb Haemost 3:2219-27. 2005
    ..In order to correct the primary von Willebrand factor (VWF) defect and avoid supra-physiologic plasma levels of factor VIII, a pure VWF concentrate almost devoid of FVIII was developed and used in France since 1989...
  42. ncbi Patterns of changes of anti-ADAMTS13 after plasma exchange
    P M Mannucci
    J Thromb Haemost 4:1405-6. 2006